Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Events

03 Jun 2017 - 05 Jun 2017
07 Jun 2017 - 09 Jun 2017

Hong Kong Hospital to Acquire Accuray Radixact Systems

By HospiMedica International staff writers
Posted on 04 Jan 2017
Print article
Image: The Radixact system (Photo courtesy of Accuray).
Image: The Radixact system (Photo courtesy of Accuray).
Accuray Incorporated (Sunnyvale, CA, USA) has signed an agreement with Hong Kong Sanatorium & Hospital [HKSH] (Happy Valley, Hong Kong) for the acquisition of three Radixact systems to provide clinicians and their patients’ access to advanced radiation therapy.

Out of the three Radixact systems, two will replace the existing TomoTherapy systems, while one will be installed in a new bunker. As per the agreement, HKSH's existing CyberKnife M6 system will also be upgraded with the latest features for motion management and treatment efficiency. With this, HKSH will become the first hospital in Asia to have both the Radixact and CyberKnife M6 systems for treating patients.

Following the agreement with Accuray, HKSH will now be able to treat the full range of cancer patients by using the Radixact system, considered to be the next-generation helical radiation therapy technology. Accuray’s Radixact systems will allow HKSH to deliver precise radiation treatments and adjust the therapy according to changes in tumor size, shape and location, as well as subtle changes in the location of organs and other healthy tissue.

"HKSH has a well-earned reputation for high-quality patient care based on advanced knowledge, expertise and technology. We are honored to expand Accuray's role in helping their team meet the needs of their rapidly growing patient population. HKSH will be the first hospital in Asia to have both the Radixact and CyberKnife M6 Systems available for patient treatments. This commitment shows confidence in our new Radixact System and in the Accuray team's ability to help the Hospital provide 'Quality in Service; Excellence in Care,'" said Josh Levine, President and CEO of Accuray.

"We are excited to build on the previous experience we have had with the TomoTherapy platform by moving to the next generation helical platform from Accuray. The TomoTherapy platform has enabled us to treat a wide range of cancer patients. The CyberKnife M6 and Radixact Systems, together, are complementary technologies that will enable us to offer each cancer patient the advanced radiation therapy best suited to precisely treating their disease while minimizing side effects," said Mr. Wyman Li, Administration Manager of HKSH.

"Hong Kong Sanatorium & Hospital has had great success in the treatment of cancer, the number one cause of death in Hong Kong. We are excited to build on our initial work with Accuray to offer state-of-the-art advanced radiation treatments to patients. The Radixact and CyberKnife M6 Systems' unique modalities and precision will enable us to meet growing demand for high quality treatment and will play a key role in the armamentarium of state-of-the art technologies that form the backbone of the Hospital's arsenal against cancer," he added.

Related Links:
Accuray
Hong Kong Sanatorium & Hospital

Print article
Fluke Biomedical

Channels

Copyright © 2000-2017 Globetech Media. All rights reserved.